Zobrazeno 1 - 10
of 101
pro vyhledávání: '"Mónica Jorge"'
Autor:
Mónica Jorge Carvalho deFigueiredo, Stanislav Zvanovec, Rafael Pérez‐Jiménez, Luis Filipe Mesquita Nero Moreira Alves
Publikováno v:
IET Optoelectronics, Vol 17, Iss 4, Pp 87-90 (2023)
Externí odkaz:
https://doaj.org/article/dab0879517754a409adc823ecb212a08
Autor:
Nieves Martínez-Lago, Ana Fernández-Montes, Marta Covela, Elena M. Brozos, Juan De la Cámara, José C. Méndez Méndez, Mónica Jorge-Fernández, Antía Cousillas Castiñeiras, Cristina Reboredo, David Arias Ron, María L. Pellón Augusto, Paula González Villarroel, Begoña Graña, Mercedes Salgado Fernández, Alberto Carral Maseda, Francisca Vázquez Rivera, Sonia Candamio Folgar, Margarita Reboredo López, On behalf of the Galician Research Group on Digestive Tumors (GITuD)
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background Outcomes are poorer in metastatic colorectal cancer (mCRC) patients with BRAF V600E mutations than those without it, but the effect of these mutations on treatment response is unclear. This real-world study assessed the effects of
Externí odkaz:
https://doaj.org/article/0205a0ed5fdf486f96be2430c7159205
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
de Figueiredo, Mónica Jorge Carvalho, Zvanovec, Stanislav, Pérez‐Jiménez, Rafael, Alves, Luis Filipe Mesquita Nero Moreira
Publikováno v:
IET Optoelectronics (Wiley-Blackwell); Aug2023, Vol. 17 Issue 4, p87-90, 4p
Publikováno v:
Dermatología Argentina. 28:37-39
La agenesia de la vena cava inferior infrarrenal es una malformación infrecuente. Habitualmente es un hallazgo imagenológico, aunque puede manifestarse con disnea, falla cardíaca, trombosis o úlceras. La asociación de agenesia de la vena cava in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a9fa92cb22e0b2a5ab7ae2fbd3dbc80c
https://doi.org/10.47196/da.v28i1.2184
https://doi.org/10.47196/da.v28i1.2184
Autor:
Rosa López, Y. Vidal Insua, Claudia Alejandra Duque Romero, Mónica Jorge, M. Salgado, M. Covela, J. Méndez, M Carmona, G. Quintero Aldana, Margarita Reboredo, A. Fernández Montes, Sonia Candamio, L. Vázquez Tuñas
Publikováno v:
Clinical and Translational Oncology. 22:495-502
Panitumumab is extensively used for RAS-WT metastatic colorectal cancer. This study assessed the efficacy and safety of panitumumab plus first-line chemotherapy [docetaxel (DOC) and cisplatin (CIS)] in treatment-naive advanced gastric or gastro-oesop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11a8d4d5e8232d73f2f360ae7f10e0ff
https://doi.org/10.1007/s12094-019-02151-6
https://doi.org/10.1007/s12094-019-02151-6
Autor:
Antonieta Salud, Jorge Barriuso, R. Jimeno, C. Romero, Fernando Rivera, Pilar García-Alfonso, Margarita Reboredo, Mónica Jorge, J. C. Méndez, Elena Asensio Martínez, Nerea Muñoz-Unceta, V. Arrazubi, Marta Izquierdo-Manuel, P. Jiménez-Fonseca, C. Lopez
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose The phase III ToGA trial established cisplatin, fluoropyrimidine and trastuzumab as the standard treatment in HER2-positive advanced gastric cancer (AGC). However, as demonstrated in HER2-negative AGC, oxaliplatin-based regimens could improve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94e5a9ec73f3e022cb8d0fe3efb80894
http://europepmc.org/articles/PMC6779679
http://europepmc.org/articles/PMC6779679
Autor:
Mónica Jorge Fernández, Maria Luz Pellon Augusto, J. Méndez, Ana Montes, Juan de la Cámara Gómez, Mercedes Salgado Fernández, Margarita Reboredo Lopez, Nieves Martinez Lago, Guillermo Alfonso Quintero Aldana, Paula González Villaroel, Marta Covela Rúa, Jesús García Gómez, Begoña Graña Suárez
Publikováno v:
Cancer Medicine
Purpose The phase III VELOUR trial demonstrated efficacy with combined FOLFIRI‐aflibercept in patients with metastatic colorectal cancer previously treated with oxaliplatin with or without bevacizumab versus placebo. The effect of FOLFIRI‐afliber
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae65e3bd50f9a60867938d42f4c8e9d0
http://europepmc.org/articles/PMC6434192
http://europepmc.org/articles/PMC6434192
Autor:
Montes, Ana Fernández, Martinez-Lago, Nieves, Gomez, Juan de la Cámara, Vázquez, Elena María Brozos, Folgar, Sonia Candamio, Campos, Marta Carmona, Castiñeiras, Antía Cousillas, Rúa, Marta Covela, Martín, Elena Gallardo, Villarroel, Paula González, Suarez, Begoña Graña, Fernández, Mónica Jorge, Augusto, María Luz Pellón, Aldana, Guillermo Quintero, Reinoso, Carlos Romero, Fernández, Mercedes Salgado, Rivera, Francisca Vázquez, Álvarez, Ana Ayuso, Culqui, Dante R., Méndez, José Carlos Méndez, Group, RIGhT-sens Working Group RIGhT-sens Working
Publikováno v:
Healthcare
Volume 9
Issue 6
Healthcare, Vol 9, Iss 665, p 665 (2021)
Repisalud
Instituto de Salud Carlos III (ISCIII)
Volume 9
Issue 6
Healthcare, Vol 9, Iss 665, p 665 (2021)
Repisalud
Instituto de Salud Carlos III (ISCIII)
Background: In recent years, abundant scientific evidence has been generated based on clinical trials (CT) in the field of oncology. In spite of this, there are still major disagreements among the group when it comes to establishing a treatment and t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2286280bb7575ab41877fefa5864a4d
Autor:
Paula Cerdá, Elvira Buxó, Eduardo Ceballos, Lorena Paris, Antia Cousillas, Jorge Aparicio, Nieves Martinez Lago, Alberto Molero, Silvia Díaz-Cerezo, Raquel Molina, Carlos Romero, Ricardo Yaya, Laura Diaz-Paniagua, María Ortega, Mónica Jorge, Federico Longo, Ana Montes, Maria Luz Pellon, Pedro Lopez Leiva, Min-Hua Jen, Alfonso Martín Carnicero, Ana Maria Lopez, Guillermo Quintero, Sergio de la Torre, Elena Brozos, Beatriz García-Paredes
Publikováno v:
FUTURE ONCOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Aims: To obtain real-world data on ramucirumab use and effectiveness for the treatment of advanced gastric cancer (AGC) or gastroesophageal junction adenocarcinoma (GEJ). Methods: Observational, retrospective study carried out in 20 Spanish hospitals
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::030a84cb2d8164ed6ed0b45b3e7668ff
https://pubmed.ncbi.nlm.nih.gov/33590772
https://pubmed.ncbi.nlm.nih.gov/33590772